Sunflower Pharmaceutical Evaporation of Market Value Nearly 600 million Companies: Homicide is its personal behavior

category:Hot
 Sunflower Pharmaceutical Evaporation of Market Value Nearly 600 million Companies: Homicide is its personal behavior


Yesterday morning, a news Guan Yanbin, former chairman of Sunflower Pharmaceutical Industry, was arrested on suspicion of intentional homicide detonated the network. Yesterday afternoon, Shenzhen Stock Exchange Sunflower Pharmaceutical Industry issued a letter of concern asking it to respond to and disclose information about whether the companys actual controller has changed before 11 days. Respondents from Sunflower Pharmaceutical Industry told Beijing Youth Daily that Guan Yanbin was the former chairman of the company and resigned at the end of last year. The case was the personal behavior of shareholders.

Market value evaporated nearly 600 million yuan yesterday

The company calls homicide an individual act of shareholders

Affected by the above news, Sunflower Pharmaceutical shares fell. As of yesterday afternoons close, Sunflower Pharmaceutical shares fell 5.27%, to 18.17 yuan, trading 1.18 billion yuan a day, and market value evaporated nearly 600 million yuan.

In the afternoon of the same day, the relevant personnel of Sunflower Pharmaceutical Industry responded to the reporter of Beiqing Daily, saying that Guan Yanbin was the former chairman of the company. He resigned at the end of December 2018 and is not currently serving as Director Gao in the listed company. This is the individual behavior of shareholders, and the company is not in a position to comment on it.

Regarding the impact of the incident on the company, the above-mentioned stakeholders said that the company is also concerned about the relevant situation, but the specific matters and follow-up issues are subject to the company announcement.

Yesterday evening, Sunflower Pharmaceutical Industry responded to the inquiry letter of Shenzhen Stock Exchange. The announcement said that the company had paid attention to the relevant media reports. According to the family members concerned, the case is still under investigation and processing, and neither party has any major obstacles. This case is caused by personal disputes, and does not involve third parties unrelated to family members, nor does it involve business operations of the company. It also said that the companys management is orderly and effective, the control right is stable, and the first quarters operating performance keeps growing and continues to improve.

In the announcement, Sunflower Pharmaceutical also promised to fulfill its disclosure obligations as scheduled if the companys actual controllers changed.

Guan Yanbin is still the actual shareholder of the company

Arrest on suspicion of intentional homicide

Sunflower Pharmaceutical Industry, headquartered in Harbin, is a large private pharmaceutical enterprise. The national enterprise credit information publicity system shows that Sunflower Group was established in September 2005 with registered capital of 584 million yuan, mainly engaged in investment and investment management, enterprise planning, pharmaceutical technology development and other businesses. In 2014, Sunflower Pharmaceutical Industry was listed on the Shenzhen Stock Exchange. At present, Guan Yanbin is still the actual controller of the company.

Guan Yanbin, born in 1954, is now 65 years old. From his resume, it is not difficult to find that in the past 65 years, Guan Yanbin has basically followed suit. In 1979, Guan Yanbin, then Secretary of the Youth League Committee of the Second Light Bureau of Wuchang County, resigned as director of a small brick and tile factory of a light and light enterprise on the verge of bankruptcy. Starting from the fund-raising of more than 5,000 yuan, he transformed the enterprise into plastic products, and in a short period of five years, he expanded the enterprise and made it stand out in the local market.

In 1985, he borrowed money from Italy to introduce ultra-wide film blowing units, becoming the first person in Songhua River region to dare eat foreign crabs. At that time, the enterprise developed into a pillar enterprise in Wuchang County and a leading enterprise in plastics industry in Heilongjiang Province. In 1989, it was promoted to a national second-class enterprise and a national fixed-point agricultural film production enterprise. In 1994, Guan Yanbin transformed Wuchang Plastic Factory into the first head of joint-stock enterprise in the former Songhua River area of Heilongjiang Province.

In 1998, Guan Yanbin led 48 shareholders of the plastics factory, totaling 11 million yuan, and purchased the original Wuchang Pharmaceutical Factory, which had been shut down for nine months and was insolvent, and renamed it Sunflower Pharmaceutical Industry.

After more than 20 years of development, Sunflower Pharmaceutical Industry has ranked among the Top 100 Chinese Pharmaceutical Business, Top 50 Chinese Pharmaceutical Industry Growth, and Heilongjiang Pharmaceutical Leading Enterprise.

The reporter of Beiqing Daily noticed that Guan Yanbins last appearance in the publics vision was probably at the time of changing his commander-in-chief. At that time, Sunflower Pharmaceutical Industry issued an announcement saying, Guan Yanbin applied to resign from the third board of directors, chairman and general manager of the company in order to give young people more opportunities and optimize the management team in the long-term development of the company due to his personal age. At the same time, he resigned from the position of member of the strategic committee of the third board of directors.

On February 1, Sunflower Pharmaceutical Company issued a further announcement that the board of directors of the company elected Guan Yuxiu as chairman of the companys third board of directors, and Guan Yi as member of the companys third board of directorsstrategic committee and convenor of the boards strategic committee. Guan Yuxiu and Guan Yi are both Guan Yanbins daughters.

According to media reports, less than a month after Guan Yanbin resigned, he was arrested by the Peoples Procuratorate of Jean-Hu Road District in Daqing on suspicion of intentional homicide, and the case is still under investigation. According to reports, Guan Yanbin and his ex-wife had a physical conflict. In the scuffle, Guan Yanbin lost his hand and beat his ex-wife into a vegetative man, which was under the control of the police. His ex-wife was in a coma.

According to public information, Guan Yanbins ex-wife is Zhang Xiaolan, who has been the manager, director and deputy general manager of Sunflower Pharmaceutical Supply Department.

On July 12, 2017, Sunflower Pharmaceutical Industry announced that the couple Guan Yanbin and Zhang Xiaolan, the companys actual controllers, had gone through the divorce formalities and terminated their marriage. The actual controller of the company was changed from Guan Yanbin and Zhang Xiaolan to Guan Yanbin.

According to relevant information, when the Wuchang Pharmaceutical Factory was restructured into Sunflower Pharmaceutical Industry in that year, Guan Yanbins share ratio was 59.85%, Zhang Xiaolans share ratio was 0.76%, but when the two divorced, Guan Yanbins property was not divided up. Instead, Zhang Xiaolans 649.7 million shares in Sunflower Pharmaceutical Industry, 76.01 million shares in Sunflower Group and 1.28 million shares in Jinkui Group were all given to Guan Yanbin. According to the market value at that time, the divorce gave Guan Yanbin about 63 million yuan.

Letter of Concern from Shenzhen Stock Exchange

Require to fulfil the obligation of information disclosure

Yesterday afternoon, Shenzhen Stock Exchange Sunflower Pharmaceutical Industry issued a letter of concern requesting it to verify and give written explanations on whether the companys actual controllers have changed, the measures it has taken and plans to take, and whether the companys production and operation activities have been affected.

In the letter of concern, the Shenzhen Stock Exchange also asked Sunflower Pharmaceutical Industry to indicate whether the exercise of shareholder rights by the parties concerned is limited, including but not limited to voting rights, whether the company should disclose non-disclosure or non-timely disclosure, whether it violates relevant provisions, etc. The reporter of Beiqing Daily noticed that Shenzhen Exchange not only required Sunflower Pharmaceutical Industry to reply and disclose before 11 days, but also copied to the Supervisory Office of Listed Companies of Heilongjiang Securities Regulatory Bureau. It also reminded Sunflower Pharmaceutical Industry to comply with laws, regulations and relevant provisions to fulfill its obligation of information disclosure. In the evening of the same day, Sunflower Pharmaceutical Industry issued a bulletin disclosing its first quarter performance forecast of 2019. During the reporting period, net profit was 15.3884 million yuan to 16.8439 million yuan, an increase of 5% to 15% over the same period. For the reasons for the performance growth, Sunflower Pharmaceutical said that during the reporting period, the companys product sales revenue steadily increased in the same period last year with a high base, maintaining a good growth momentum, and driving the growth of overall revenue and net profit. Source of this article: Gu Ying_NN6577, responsible editor of Beiqing Net-Beijing Youth Daily

In the letter of concern, the Shenzhen Stock Exchange also asked Sunflower Pharmaceutical Industry to indicate whether the exercise of shareholder rights by the parties concerned is limited, including but not limited to voting rights, whether the company should disclose non-disclosure or non-timely disclosure, whether it violates relevant provisions, etc.

The reporter of Beiqing Daily noticed that Shenzhen Exchange not only required Sunflower Pharmaceutical Industry to reply and disclose before 11 days, but also copied to the Supervisory Office of Listed Companies of Heilongjiang Securities Regulatory Bureau. It also reminded Sunflower Pharmaceutical Industry to comply with laws, regulations and relevant provisions to fulfill its obligation of information disclosure.

In the evening of the same day, Sunflower Pharmaceutical Industry issued a bulletin disclosing its first quarter performance forecast of 2019. During the reporting period, net profit was 15.3884 million yuan to 16.8439 million yuan, an increase of 5% to 15% over the same period.

For the reasons for the performance growth, Sunflower Pharmaceutical said that during the reporting period, the companys product sales revenue steadily increased in the same period last year with a high base, maintaining a good growth momentum, and driving the growth of overall revenue and net profit.